DESTINY-Endometrial01 phase 3 Trial of Enhertu initiated as first-line therapy in patients with HER2 expressing primary advanced or recurrent endometrial cancer

CAR-T Digest - August 2020

Weekly Digest - June 2025

09 June 2025: DESTINY-Endometrial01 phase 3 Trial of Enhertu initiated as first-line therapy in patients with HER2 expressing primary advanced or recurrent endometrial cancer

Daiichi Sankyo and AstraZeneca have initiated the Phase 3 DESTINY-Endometrial01 trial of ENHERTU (trastuzumab deruxtecan) for first-line treatment of HER2-expressing, pMMR advanced or recurrent endometrial cancer
The trial compares ENHERTU plus rilvegostomig or pembrolizumab to standard platinum-based chemotherapy (carboplatin + paclitaxel) with pembrolizumab
Conducted in collaboration with GOG Foundation and ENGOT, the study targets HER2 IHC 3+/2+ patients, a subgroup linked with aggressive disease and limited current treatment options
Enhertu, a HER2-directed ADC, previously showed positive results in DESTINY-PanTumor02, supporting its potential use in this cancer type where no HER2-targeted drugs are yet approved. Latest clinical data were presented at the 2025 ASCO Annual Meeting in a poster session